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Polymorphisms of xenobiotic-metabolizing enzymes, responsible for individual differences in
metabolic activation and detoxification reactions, may profoundly modulate the effects of chemical
carcinogens. In the case of genotoxic carcinogens, differences in biological effects due to genetic
polymorphisms can be evaluated by cytogenetic methods such as the analysis of chromosomal
aberrations (CAs), sister chromatid exchanges (SCEs), micronuclei (MN), and changes in
chromosome number. These techniques can be applied to any exposure known to induce such
alterations, without additional method development for each exposing agent. The influence of
polymorphic genes on the cytogenetic effects of a carcinogen can quickly be tested in vitro using
metabolically competent cells collected from donors representing different genotypes or
phenotypes. For instance, erythrocytes from individuals positive for glutathione S-transferase Ti
(GST1I) express GSTT1, whereas GSTT1-null donors, having a homozygous deletion of the GSTT1
gene, completely lack this detoxification enzyme. This deficiency results in highly increased
sensitivity to SCE induction in whole-blood lymphocyte cultures by 1,2:3,4-diepoxybutane, a
reactive metabolite of 1,3-butadiene. The same cytogenetic techniques can also be applied as
effect biomarkers in studies of human populations exposed to genotoxic carcinogens. For
example, elevated rates of chromosome damage have been detected among smokers lacking
glutathione S-transferase Ml (GSTM1-null genotype), and the baseline level of SCEs seems to be
increased in GSTT1-null individuals. Information obtained from cytogenetic studies of genetic
polymorphisms can be used, for example, to recognize the genotoxically relevant substrates of the
polymorphic enzymes, to identify genotypes that are susceptible to these genotoxins, to improve
in vitro genotoxicity tests utilizing human cells, to increase the sensitivity of cytogenetic endpoints
as biomarkers of genotoxic effects in humans, and to direct mechanistic studies and cancer
epidemiology. Environ Health Perspect 105(Suppl 4):829-835 (1997)
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Introduction
Susceptibility to the hazardous action of result in chromosome instability syndromes
chemicals may derive from genetic or characterized by defects of DNA repair or
acquired characteristics ofthe individual. In recombination, increased baseline or
the case ofgenotoxic carcinogens, suscepti- induced chromosome damage, and high
bility can be associated with individual dif- cancer incidence-may also increase cancer
ferences, e.g., in the efficiency ofcarcinogen in heterozygotes (1,2). Besides such het-
metabolism or in the ability to repair DNA erozygotes, sensitivity to genotoxic carcino-
lesions induced by the carcinogen. Certain gens could be associated, for example, with
recessive genes, which among homozygotes subtle genetic polymorphisms influencing
This paper was prepared as background for the Workshop on Susceptibility to Environmental Hazards con-
vened by the Scientific Group on Methodologies for the Safety Evaluation of Chemicals (SGOMSEC) held
17-22 March 1996 in Espoo, Finland. Manuscript received at EHP 5 November 1996; accepted 18 November
1996.
Address correspondence to Dr. H. Norppa, Department of Industrial Hygiene and Toxicology, Finnish
Institute of Occupational Health, Topeliuksenkatu 41 a A, FIN-00250 Helsinki, Finland. Telephone: 358-9-
4747336. Fax: 358-9-4747208. E-mail: hnor@occuphealth.fi
Abbreviations used: ALDH2, aldehyde dehydrogenase 2; CAs, chromosomal aberrations; CYPlAl,
cytochrome P4501A1; CYP2D6, cytochrome P-4502D6; FISH, fluorescence in situ hybridization; GSTM1, glu-
tathione S-transferase Ml; GSTT1, glutathione S-transferase Ti; MN, micronuclei; NAT2, aacetyltransferase 2;
SCEs, sister chromatid exchanges.
DNA repair processes, although such traits
have not yet been found in the human
population. On the other hand, studies of
individual differences in xenobiotic metab-
olism have revealed an increasing number
ofpolymorphic enzymes that are involved
in the metabolism ofcarcinogens (3,4).
Biotransformation, involving metabolic
activation and detoxification, plays a cen-
tral role in determining the ultimate effects
of exposure to chemical carcinogens.
Depending on the enzyme, there may be
one or several mutant alleles that produce
enzyme variants with reduced or increased
efficiency in comparison with the wild-type
form. In some cases, such as the null geno-
types of glutathione S-transferases M1
(GSTMI) and Ti (GSTTI), the functional
enzyme is completely missing (3).
Numerous epidemiological studies
have indicated an over-representation of
some metabolic genotypes or phenotypes
in various forms ofcancer, suggesting that
those individuals are excessively prone to
such diseases (3,4). With the possible
exception of tobacco smoking in, for
example, lung cancer associated with the
GSTMI and cytochrome P450 (CYP)
polymorphisms, epidemiology is not usu-
ally able to exactly pinpoint the exposures
that are responsible for the findings, as the
critical influence of carcinogen-metaboliz-
ing enzymes occurs several years before
exposure-associated cancer develops.
The question ofindividual sensitivity to
genotoxic carcinogens can also be viewed
by studying the involvement of genetic
polymorphisms in determining genotoxic
response after exposure to specific car-
cinogens. For this purpose, methods based
on genotoxicity assays with human cells,
such as cytogenetic techniques, are very
useful as they can be applied to any expo-
sures known to produce such alterations.
Thus, no specific method development for
each new exposing agent is required, and
the net effect ofcomplex exposures can be
evaluated. Differences between genotypes
can be assessed by comparing cytogenetic
responses after in vitro exposure or in
individuals exposed to the genotoxins of
interest in vivo.
The present review will concentrate
on the application of cytogenetic bio-
markers-chromosomal aberrations
(CAs), sister chromatid exchanges (SCEs),
micronuclei (MN), and numerical chro-
mosome changes-in studies ofindividual
susceptibility related to polymorphisms of
carcinogen-metabolizing enzymes.
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Cytogenetic Parameters
The four cytogenetic parameters already
mentioned-CAs, SCEs, MN, and numeri-
cal chromosome alterations-are all based
on microscopic analyses ofcell specimens,
but each ofthem measures a different geno-
toxic phenomenon. In humans, cytogenetic
alterations are most often scored from
peripheral lymphocytes after they have been
stimulated to divide in culture by a mitogen,
e.g., phytohemagglutinin (5).
CAs are structural alterations, breaks
and rearrangements, in chromosomes, usu-
ally observed in metaphase-blocked cells
using conventional microscopy (5). In
principle, chromosomal aberrations can be
divided into chromosome-type lesions-
produced by ionizing radiations and some
chemical clastogens in Go-GI-stage cells-
and chromatid-type lesions that ionizing
radiation causes in S-G2-stage cells and
that are the main type of aberrations
induced by most (S-phase dependent)
chemical clastogens. Chromosome-type
rearrangements, such as translocations and
dicentrics inspected in biological dosimetry
of radiation, can also be analyzed using
chromosome painting based on fluores-
cence in situ hybridization (FISH) with
chromosome-specific DNA probe libraries
(6). Recently, a simplified FISH method
to score chromosome breakage and alter-
ations ofchromosome number, using tan-
dem DNA probes specific for a region in
chromosome number 1, was reported (7).
Polymerase chain reaction-based methods
for the analysis oflymphocyte-specific ille-
gitimate chromosome recombination
involving human immunoglobulin or
immune receptor loci and considered to
depict genetic instability have also been
described (8,9). In two recent independent
reports, increased rates of CAs in periph-
eral lymphocytes were shown to be associ-
ated with later development of cancer
(10,11). Thus, the analysis of CAs is
presently considered to be the cytogenetic
method of choice in studies of human
exposure to genotoxic carcinogens. A wide
range ofgenotoxins have shown CA induc-
tion in vitro and in vivo. Known in vivo
inducers ofCAs in humans indude ionizing
radiations, alkylating cytostatics, tobacco
smoking, benzene, and styrene.
SCEs represent symmetrical exchanges
ofDNA segments between the sister chro-
matids ofa duplicated metaphase chromo-
some and (because the sister chromatids
are supposed to be equal) are not them-
selves mutations. SCEs are formed during
the S-phase of the cell cycle and are
efficiently induced by, for example, UV
light and many chemical genotoxins, espe-
cially the S-phase dependent clastogens
(12). The fact that each cell examined
yields an SCE score makes the technique a
very powerful tool for the assessment of
differences between genotypes, particularly
in vitro. In human lymphocytes in vivo,
tobacco smoking, alkylating cytostatics,
and ethylene oxide are well-documented
SCE inducers.
Micronuclei are small additional
nuclei observable in interphase cells. They
are formed from acentric chromosome- or
chromatid-type fragments and whole
chromosomes that have lagged behind in
cell division, being left outside both
daughter nuclei (13). Because of their
dual origin (fragments or whole chromo-
somes), MN induction can be triggered
by either clastogens or agents influencing
the mitotic apparatus, such as spindle poi-
sons. As cell division is a prerequisite for
MN formation, MN in cultured periph-
eral lymphocytes are usually analyzed from
cytokinesis-blocked cells, to identify cells
that have divided once in culture (14).
MN can also be scored in exfoliated cells of
buccal, nasal, esophageal, bronchial, or
urothelial mucosa (15). The presence of
whole chromosomes in MN can be
checked by identifying centromeric DNA
sequences or kinetochore proteins in the
MN (16,17). MN analysis appears to be a
good in vitro tool to investigate the effects
ofclastogens and agents (aneuploidogens)
that induce numerical abnormalities of
chromosomes. In vivo, increased MN fre-
quencies have been associated with expo-
sure to ionizing radiation, aging, and
gender (18). In buccal or nasal mucosa,
MN induction has clearly been shown for
various ethnic tobacco-chewing habits (15)
and exposure to formaldehyde (19).
The development ofFISH techniques
has made it possible to detect, in a very
simple manner, the copy numbers ofany
specific human chromosome for which a
centromeric DNA probe is available (20).
Both aneuploid and polyploid cells are
identified, although hyperdiploids cannot
usually be distinguished from polyploids
unless probes for more than two chromo-
somes are used. The tandem FISH assay
mentioned above provides information on
both structural and numerical chromoso-
mal aberrations (7). Such analyses have
thus far been used as biomarkers in humans
only in a few cases, although they can be
applied, besides peripheral lymphocytes, to
anyhuman tissue available.
Genetic Polymorphisms and
CytogeneticAssays in Vrtro
The involvement of a polymorphism in
determining the cytogenetic effects of a
specific genotoxin can easily be tested in
vitro in cultured cells collected from
donors representing different genotypes or
phenotypes. A requirement is, of course,
that the cells used adequately express the
polymorphic condition, i.e., in the case of
metabolic genes, the enzyme in question.
In the examples available, peripheral lym-
phocytes have been used, which are also
the most convenient choice, because of
easyavailability andwell-established culture
techniques (Table 1).
The first example of the utilization of
the in vitro approach was the study of
Wiencke et al. (21) in which the effects of
two isomeric epoxides, trans-stilbene oxide
and cis-stilbene oxide, on SCEs were stud-
ied in cultured lymphocytes from persons
able or unable to conjugate trans-stilbene
oxide with glutathione. This trait reflects
the genetic polymorphism ofGSTM1 that
is expressed in the leukocytes ofthe conju-
gators (corresponding to the GSTMI-posi-
tive genotype, with at least one copy ofthe
intact gene) but is totally absent from the
nonconjugators (the GSTMI-null geno-
type having a homozygous deletion of the
gene). The nonconjugators were clearly
more sensitive than the conjugators to SCE
induction by trans-stilbene oxide, a sub-
strate of GSTM1; no clear difference was
observed between the phenotypes in tests
with cis-stilbene oxide, which is not a good
substrate for GSTM1.
GSTM1-mediated glutathione conjuga-
tion also appeared to be involved in the case
of1,2-epoxy-3-butene (22), as lymphocytes
of GSTMI-null donors were more sensitive
than GSTMI-positive donors to SCE
induction by this epoxide metabolite of
1,3-butadiene. Another epoxide, styrene
7,8-oxide, a metabolite ofstyrene, showed
the same SCE induction in both genotypes,
and appeared, therefore, not to be depen-
dent on the GSTM1-catalyzed detoxifica-
tion (22). The GSTM1 genotype (or
phenotype) did not influence SCE induc-
tion by two other reactive metabolites of
1,3-butadiene-1,2:3,4-diepoxybutane and
3,4-epoxybutene-1,2-diol (23-25).
Hallier et al. (26) described another
polymorphism, identified by the presence
or absence ofmethyl bromide glutathione
conjugation in erythrocytes. After treatment
ofwhole-blood samples, the nonconjuga-
tors' lymphocytes showed SCE induction
by methyl bromide, methylene chloride,
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Table 1. Results of in vitro studies on the influence of genetic polymorphisms of carcinogen-metabolizing enzymes on the induction of chromosomal aberrations, sister chro-
matid exchanges, and micronuclei in cultured human lymphocytes.
Genotype or Cytogenetic Risk genotype or
phenotype studied Chemical end point phenotypea Reference
GSTMi activity trans-Stilbene oxide SCEs GSTM1-deficient Wiencke et al. (21)
cis-Stilbene oxide SCEs None Wiencke et al. (21)
DEB SCEs None Wiencke and Kelsey (24)
GSTM1 genotype 1,2-Epoxy-3-butene SCEs GSTM1-null Uuskula et al. (22)
Styrene 7,8-oxide SCEs None Uuskula et al. (22)
DEB SCEs None Norppa etal. (23)
Landi et al. (31)
EBD SCEs None Bernadini et al. (25)
GSTIi activity Methyl bromide SCEs Nonconjugator Hallier et al. (26)
Ethylene oxide SCEs Nonconjugator Hallier et al. (26)
Dichloromethane SCEs Nonconjugator Hallier et al. (26)
DEB SCEs Nonconjugator Norppa et al. (23)
DEB-sensitivity DEB SCEs, CAs DEB-sensitive Norppa et al. (23); Wiencke and Kelsey(24);
Wiencke et al. (27,28,32)
Kelsey et al. (29,30)
Landi et al. (31)
1,2-Epoxy-3-butene SCEs DEB-sensitive Wiencke and Kelsey(24)
Nitrogen mustard SCEs None Wiencke and Kelsey(24)
GSTT1 genotype DEB SCEs, MN GSTT1-null Norppa etal. (23,33); Kelsey et al. (30);
Landi et al. (31)
Pelin etal. (34)
EBD SCEs None Bernadini et al. (25)
Styrene 7,8-oxide SCEs GSTT1-null Norppa et al. (39)
ALDH2genotype Hydroquinone SCEs ALDH2-deficient Morimoto and Takeshita (41)
Abbreviations: ALDH2, aldehyde dehydrogenase 2; CAs, chromosomal aberrations; DEB, 1,2:3,4-diepoxybutane; DEB sensitivity, enhanced SCE response to 1,2:3,4-diepoxybu-
tane; EBD, 3,4-epoxy-1,2-butanediol; GSTM1, glutathione S-transferase Mi; GSTT1, glutathione S-transferase Ti; MN, micronuclei; SCEs, sister chromatid exchanges.
"Genotype or phenotype giving an enhanced cytogenetic response.
and ethylene oxide while no such effects
could be seen in the conjugators. The phe-
notypes identified probably represented
GSTT1-positive (at least one copy of the
gene) and GSTTI-null (gene homozy-
gously deleted) genotypes, as GSTT1 is an
erythrocytic enzyme.
The GSTT1 polymorphism was recently
also shown to explain individual differences
in sensitivity to 1,2:3,4-diepoxybutane
(DEB), a diepoxide metabolite of 1,3-buta-
diene. Early studies ofWiencke et al. (27)
demonstrated that humans can be dassified
as DEB sensitive (about 20% ofthe persons
studied) or DEB resistant on the basis of
SCE induction by DEB in cultured lym-
phocytes. The DEB-sensitive donors also
showed an enhanced induction ofCAs by
DEB (28) and had an elevated baseline
rate of SCEs (29). Recent expansions of
these studies have demonstrated that all
(23,30,31) or the majority (67%) (32) of
the DEB-sensitive donors have the GSTTJ-
null genotype. Lymphocytes from GSTTI-
null donors also showed an enhanced
induction ofMN by DEB in vitro (33). In
our experiments, erythrocytes from DEB-
sensitive donors had no detectable GSTT1
activity (23), and the SCE responses of
GSTTI-null and positive individuals
showed nooverlapping (23,31,34).
It is presently unclear what the
DEB-sensitive GSTTI-positive individuals
described by Wiencke et al. (32) actually
represent. A point mutation resulting in a
loss ofGSTT1 activity, which would not
be detected by usual GSTTI genotyping,
has been described byWarholm et al. (35);
this mutation was, however, very rare (2
among 270 donors) in the Swedish popula-
tion studied. In cultures ofpurified lym-
phocytes-with no erythrocytes and no
GSTT1-the DEB-resistant (GSTTI-posi-
tive) donors showed very similar SCE
induction as the DEB-sensitive (GSTTI-
null) donors (34), and the addition ofery-
throcytes from a resistant person to the
purified lymphocytes ofa sensitive person
removed the DEB sensitivity (36).
In Salmonella typhimurium transfected
with human GSTTI, the expression of
GSTT1 activity increased the mutagenicity
of DEB, thus functioning as a metabolic
activation route (37). Therefore, it would
appear that glutathione conjugation of
DEB leads to enhanced genotoxicity in
(bacterial) cells, where the target DNA is
present, while the same reaction in
erythrocytes ofwhole-blood lymphocyte
cultures prevents DEB from reacting with
DNA. Although epidemiologic studies
have shown several examples of increased
disease risk in GSTTl-null but not in
GSTTI-positive individuals (3) it may
also be possible that GSTTI activates
some tissue- or cell-specific mutagens in
humans (38).
Our recent findings suggested that the
GSTT1 nulls also show higher SCE induc-
tion by an in vitro treatment with styrene
7,8-oxide, although the effect was not
nearly as dramatic as with DEB (39). This
result appears to agree with the fact that
glutathione conjugation is a minor pathway
in styrene 7,8-oxide detoxification.
However, the proposed main detoxification
enzyme ofstyrene 7,8-oxide, microsomal
epoxide hydrolase, is also polymorphic
(3,40), albeit the significance ofthis poly-
morphism in determining epoxide hydrolase
levels in humans is still unclear. It must be
kept in mind in all studies correlating bio-
logical effects with genetic polymorphisms
that differences in mean biological responses
between genotypes are not necessarily attrib-
utable to that particular genotype, but may
also be due to such uncontrolled factors as
other unknown or unchecked polymor-
phisms, acquired differences in enzyme
levels, orexperimental variation.
The deficiency of low Km aldehyde
dehydrogenase (ALDH2), resulting in
impaired detoxification ofacetaldehyde, is
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common in Oriental populations. About
one-halfofall Japanese are either heterozy-
gotes (ALDH21/ALDH22) or homozygotes
(ALDH22IALDH22) for a mutation in
the ALDH2 gene (41). Morimoto and
Takeshita (41) observed that lymphocytes
ofALDH2-deficient donors are more sensi-
tive than those ofALDH2-proficient indi-
viduals (ALDH2I/ALDH2i) to SCE
induction by an in vitro treatment with
hydroquinone, a metabolite of benzene.
The genotype effect was higher in habitual
daily alcohol drinkers than in those who
consumed alcohol less frequently. The
authors did not provide an explanation for
these findings.
Another aspect, aside from the use of
the in vitro cytogenetic assays to identify
dependence on genetic polymorphisms, is
the influence ofgenotype data on routine
genotoxicity testing using human cells.
For instance, lymphocytes from GSTM1-
null donors will respond higher to certain
treatments than individuals with the
GSTMJ-positive genotype, and differen-
tial responses obtained, e.g., between
human whole-blood and isolated lym-
phocyte cultures, may partly be explained
by the GSTT1 activity of red blood cells
not present in purified lymphocyte
cultures. In critical cases, such as those
shown by Hallier et al. (26) for methyl
bromide, methylene chloride, and ethyl-
ene oxide, one phenotype (conjugators)
will give a negative result and another
(nonconjugators) positive.
Individual Susceptibility and
Cytogenetic Markers in Vivo
The few studies available on genetic
polymorphism and the rate ofcytogenetic
alterations in humans in vivo have almost
exclusively been performed using periph-
eral lymphocytes. Thus far, the studies
have addressed induced or baseline
cytogenetic damage in association with
polymorphisms of GSTMI, GSTTI,
cytochrome P4501AI (CYPIA1), cyto-
chrome P4502D6 (CYP2D6), and
N-acetyltransferase 2 (NAT2).
The first investigation describing an
association between genetic polymorphisms
and cytogenetic response to a genotoxic
exposure in man in vivo was the report of
van Poppel et al. (42) on a small increase in
SCEs in heavy smokers not expressing
GSTM1, as compared with GSTMl-profi-
cient heavy smokers; the effect was not
observed in moderate smokers or nonsmok-
ers. MN in sputum cells were not influenced
bysmokingorthe GSTMIphenotype (43).
Cheng et al. (44-46) observed a
significant association between the
GSTMI-null genotype and elevated SCE
frequencies (but not MN) in lymphocytes
of healthy control persons (but not of
lung cancer patients). However, the find-
ing appeared not to be associated with
smoking. CYPIAI MspI and Ile-Val
mutations and CYP2D6G to A mutations
did not influence SCE frequencies among
the controls (44).
The influence ofthe GSTMI genotype
on smoking-induced chromosome damage
was further supported byour recent studies,
which show a statistically significant associ-
ation between the GSTMI-null genotype
and elevated CA rates (but not SCE or
MN) in lymphocytes ofsmoking Italian
greenhouse workers and controls (47,48).
The effect particularly concerned chro-
matid-type aberrations. The pesticide expo-
sure of the greenhouse workers had no
significant influence on CAs, SCEs, or
MN. No dependence of the cytogenetic
biomarkers on GSTTI or NAT2 genotypes
was observed, except for a slightly higher
baseline SCE level among GSTT1-positive
donors in comparison with GSTTI-null
individuals; this finding was possibly due to
chance, as there were onlyfour GSTTI-null
subjects (47).
The preliminary results of another
recent study among Danish bus drivers
indicated an increasing gradient ofCA fre-
quencies from GSTMI-positivelNAT2 fast
acetylator genotype to GSTMI-null/
NAT2slow acetylator genotype (39). This
finding suggested that these genotypes
modulate the genotoxic effects of expo-
sures (diesel exhaust) experienced by the
bus drivers in theirwork.
Carstensen et al. (49) and Ichiba et al.
(50) studied MN in T- and B-lymphocytes
ofchimney sweeps, but could not observe
anysignificant association between MN fre-
quency and GSTMI and CYPIAI geno-
types, in connection with the occupational
exposure or smoking. Although the
GSTMI genotype itself was not signifi-
cantly associated with variations in MN fre-
quency, correlation between the frequency
of MN in T-lymphocytes and aromatic
DNA adducts in total white blood cells was
statistically significant among GSTMI-null
individuals (sweeps and controls combined)
(50). CYPIA1 MspI and Ile-Valpolymor-
phisms did not influence MN frequencies,
although the common "noninducible"
MspI genotype mllml showed significantly
higher DNAadduct levels than the tentative
high-inducible ml/m2genotype (50).
There are also studies suggesting no
influence of GSTMI genotype on cytoge-
netic damage in human lymphocytes, but
these data derive from control cultures
established for in vitro studies not designed
to reveal differences in baseline rate of
cytogenetic damage (21-23,28).
The clear difference in sensitivity to
DEB (metabolite of 1,3-butadiene) in
vitro in association with the GSTTI geno-
type (above) has also triggered in vivo
cytogenetic studies on a possible genotype
effect among 1,3-butadiene production
workers. The preliminary results of a
European study showed an increase in CA
in lymphocytes of GSTTI-null workers in
comparison with GSTTI-positive workers
(51). A study in the United States on
SCEs in 1,3-butadiene producers, how-
ever, failed to show any association with
the GSTTI genotype (30). Due to auto-
mated processes, exposure to butadiene in
the facilities studied was fairly low. The
positive European study suggested that
genotype determination may improve the
sensitivity ofcytogenetic assays in detecting
the effects oflow-level genotoxic exposures.
The American study did confirm the
higher background SCE frequency of
GSTTI-null subjects as compared with
GSTTI-positive individuals (30). Wiencke
et al. (32) calculated that the DEB sensitiv-
ity and the GSTTI genotype were the most
important factors influencing baseline SCE
frequency, explaining 37 and 27%, respec-
tively, ofthe variation observed. Smoking,
for instance, was found to explain only 6 to
16% ofthe variation. The genotype effect
was independent of smoking and was
thought to reflect exposure to internal or
ubiquitous external factors dependent on
glutathione conjugation (32). One candi-
date could be ethylene oxide, a tentative
substrate ofGSTT1 (26), formed by xeno-
biotic metabolism from endogenous ethyl-
ene. CA count was not significantly elevated
in the lymphocytes of the DEB-sensitive
subjects (28).
Morimoto and Takeshita (41) observed
that ALDH2-deficient habitual alcohol
drinkers hadhigher mean frequencyofSCEs
in lymphocytes than ALDH2-proficient
individuals who consumed alcohol daily.
This effect probably reflected the higher
acetaldehyde levels found in the peripheral
blood ofthe ALDH2-deficient subjects who
also showed an elevated level ofacetaldehyde
adducts in hemoglobin (52). Other lifestyle
factors may also play a role, since a signifi-
cant genotype effect could be shown in
smokers but not in nonsmokers (41).
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Conclusions
The relationship between human genetic
polymorphisms and genotoxicity is a new
field ofresearch and only a limited amount
of information is presently available.
Already, the data available suggest that
donor genotype can have dramatic influence
on induced or baseline levels ofcytogenetic
alterations both in vitroand in vivo.
The use of in vitro assays to test the
impact ofspecific genotypes or phenotypes
on the cytogenetic effects ofgenotoxins is
highly recommended as it will give an idea
about the biological significance ofgeno-
typic differences, which is not revealed, for
example, by enzyme activity measurements
alone. In this way, in vitro experiments
can serve as a guideline for selecting expo-
sures and genotypes to be studied in vivo.
A prerequisite is, of course, that the
polymorphisms of interest are expressed
in the cells. Adequate expression has been
shown at least for GSTM1 in human
lymphocytes and GSTT1 in erythrocytes.
The relationship between the GSTTJ
genotype and sensitivity to SCE induction
by DEB seems to be a good example ofan
exceptionally clear association.
Understanding the significance of
genetic polymorphisms in determining
genotoxic response will also have an
important influence on requirements
concerning the use of human cells in
genotoxicity testing. Some discrepancies
between negative and positive findings or
dramatically different active concentration
ranges will be explained by different
genotypes ofthe donors.
Studies of cytogenetic biomarkers
among exposed humans show that the
determination ofpolymorphisms is becom-
ing an increasingly important aspect that
may make the assays more sensitive and
more specific in identifying the effect and
the sensitive subgroups. At present, it seems
that at least GSTM1 and GSTTI genotypes
ofthe donors should be studied on a rou-
tine basis when in vivo cytogenetic effects
are concerned. Rarer genotypes can be eval-
uated only in large populations-even the
10 to 20% prevalence ofthe GSTTI-null
genotype among Caucasians may be too
low to allow evaluation if the exposure
groups are small. Besides good knowledge
in genetic toxicology and molecular genet-
ics, expertise in epidemiology is becoming
quite useful in planning such exercises, and
statistical treatment will not be valid with-
out multivariate analyses in which all ofthe
variables can be duly taken into account.
There will also be much to be learned in
risk assessment. Restricted still in most
cases to surrogate tissues, such as peripheral
lymphocytes, instead ofthe real targets of
carcinogenesis, many things can go wrong
in assessing the risk. For instance, the
expression or role ofthe critical metaboliz-
ing enzymes may vary in different tissues.
From these considerations, one arrives at
the ethical issues that are dealt with more
thoroughly elsewhere in this issue (53). It is
obvious that the cytogeneticist is faced with
ethical questions both in sample collection
and when the results of the research are
used in risk estimation. It can be gathered
from what has been presented above that
sound conclusions about the role ofgenetic
polymorphisms in determining genotoxic
risks can be achieved only when the com-
plex issue has been studied in depth.
Information obtained from cytogenetic
studies of genetic polymorphisms can be
used to recognize the genotoxically relevant
substrates ofthe polymorphic enzymes, to
identify susceptible genotypes, and to
improve the sensitivity of cytogenetic
assays both in vitro and in vivo. Such
knowledge can be utilized in mechanistic
studies and cancer epidemiology. In search
for the role ofgenetic polymorphisms in
carcinogenesis, the cytogenetic markers
form a link in the chain ofevidence which
stretches from experimental in vitro work,
through analyses of exposed humans, to
studies on cancer. Genetic polymorphisms
can be followed in all ofthese steps.
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